Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657009 | 1.00 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL2658844 | 1.00 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL2655895 | 1.00 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL2655897 | 1.00 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL15700860 | 1.00 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL2655923 | 0.75 | — | — | |
| SCHEMBL13822461 | 0.75 | PABPC1 (0.38) | PABPC1CTDSP1GAA | |
| SCHEMBL16727649 | 0.75 | — | — | |
| SCHEMBL17190305 | 0.75 | PABPC1 (0.38) | PABPC1CTDSP1GAA | |
| SCHEMBL2657636 | 0.75 | PABPC1 (0.38) | PABPC1CTDSP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299182-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | AMGEN INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2209778-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009042435-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299182-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | SLC5A1, IAPP, PTGER1 | PABPC1 1938/4885CTDSP1 2210/4885GAA 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.